文献速递神经肿瘤

TNIK在髓母细胞瘤中的亚型特异性预后影响

Subtype-specific prognostic impact of TNIK in medulloblastoma.
PubMed 文献 · J Neurooncol · 2026-05-08

本研究通过公开转录组数据集、质谱蛋白质组数据和髓母细胞瘤组织芯片免疫组化评估TNIK表达,发现TNIK在Group 3和Group 4髓母细胞瘤中显著富集,高TNIK表达在Group 4中预测较差总生存,而在SHH肿瘤中与较好结局相关,提示TNIK可作为亚型特异性预后生物标志物。

要点

  • TNIK表达在Group 3和Group 4髓母细胞瘤中较WNT和SHH亚型显著富集。
  • 高TNIK表达在Group 4中预测较差总生存,在SHH中与较好结局相关。
  • TNIK可能作为Group 4髓母细胞瘤的预后生物标志物。

核心结论

  • TNIK在髓母细胞瘤中具有亚型特异性作用,尤其在Group 4中可能作为预后生物标志物。

研究设计与样本

  • 利用公开髓母细胞瘤转录组数据集、质谱蛋白质组数据及组织芯片免疫组化分析TNIK表达。
  • 评估TNIK表达与分子亚型、总生存及既定预后标志物的关联。

主要发现

  • TNIK表达在Group 3和Group 4髓母细胞瘤中较WNT和SHH亚型显著富集。
  • 高TNIK表达在Group 4中预测较差总生存,而在SHH肿瘤中与较好结局相关。
  • 蛋白质组学分析支持上述观察结果。

临床怎么用

  • TNIK表达检测可能有助于Group 4髓母细胞瘤的风险分层。
  • TNIK在SHH亚型中的预后意义相反,需结合分子亚型解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Medulloblastoma (MB) is the most common malignant pediatric brain tumor and comprises molecularly and clinically distinct subgroups with highly variable outcomes. While survival rates exceed 80% in some subgroups, others remain associated with substantially poorer prognosis and increased risk of relapse. Current treatment includes surgery, radiation, and chemotherapy, which can result in significant long-term treatment-related morbidity. These challenges highlight the need to identify novel biomarkers and potential therapeutic targets to improve risk stratification and enable more tailored treatment approaches. The Traf2- and Nck-interacting kinase (TNIK) is a regulator of Wnt/β-catenin signaling and has been implicated in the progression of several cancers, but its role in MB remains unclear. METHODS: TNIK expression was evaluated using publicly available MB transcriptomic datasets, mass spectrometry based proteomic data, and immunohistochemical analysis of a MB tissue microarray. Associations between TNIK expression, molecular subgroups, overall survival, and established prognostic markers were assessed. RESULTS: TNIK expression was significantly enriched in Group 3 and Group 4 MBs compared to WNT and SHH subgroups. Survival analyses demonstrated distinct, subgroup-specific prognostic effects: high TNIK expression predicted inferior overall survival in Group 4, while in SHH tumors high TNIK expression levels were associated with improved outcome. These observations were supported by proteomic profiling. CONCLUSION: These findings indicate a subgroup-specific role for TNIK in MB biology and suggest its potential utility as a prognostic biomarker, particularly in Group 4 MBs.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Klaus FL, Maragkou T, Delbridge C, et al. Subtype-specific prognostic impact of TNIK in medulloblastoma. J Neurooncol. 2026. PMID: 42101697. doi:10.1007/s11060-026-05554-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。